Clinical Trial Update: Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period [Phase 3]

View source ↗

Summary

Phase 3 open-label extension of DCCR in Prader-Willi syndrome followed by a double-blind withdrawal period; trial completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prader-willi Syndrome

Drugs mentioned

• DCCR (diazoxide choline)

Snippet

Sponsor: Soleno Therapeutics, Inc. | Conditions: Prader-Willi Syndrome | Phase 3 | Status: COMPLETED